First Patient Dosed in Phase 3 Trial of Etrasimod for Moderate to Severe UC
News
The Phase 3 trial ELEVATE UC 52 evaluating Arena Pharmaceuticals’ investigational therapy etrasimod for patients with moderately to severely active ulcerative colitis has dosed its first patient. “We are pleased to ... Read more